News & Updates

Updated results from the phase III PULSAR trial show that intravitreal (IVT) aflibercept 8 mg, when administered at extended dosing intervals of up to 20 weeks, led to visual gains and anatomic improvements comparable to the 2-mg dose, with no new safety concerns over 96 weeks, in treatment-naïve individuals with neovascular age-related macular degeneration (nAMD).

A study shows that daily nasal interferon-alpha (IFN-α) spray reduces the incidence of COVID-19 among adult patients with cancer.

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes and cancer results in significantly reduced mortality and hospitalizations relative to treatment with metformin, a study has shown.

Icotrokinra—the first and only targeted oral peptide designed to selectively block the interleukin-23 receptor (IL-23R), which has been approved for the treatment of plaque psoriasis—shows multiple favourable signals for the treatment of ulcerative colitis (UC), according to updated data from the phase IIb ANTHEM-UC study.